Connective tissue disease-associated interstitial lung disease: a rheumatologist's perspective

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Autoimmune and connective tissue diseases (CTDs) frequently cause pulmonary complications.
• Interstitial lung disease (ILD) is the most common lung manifestation in CTDs.
• Specific CTDs like systemic sclerosis, rheumatoid arthritis, and inflammatory myopathies have high ILD association.

Purpose of the Study:

• To highlight the prevalence and spectrum of pulmonary involvement in CTDs.
• To emphasize the importance of screening high-risk patients for ILD.
• To discuss the role of antibody profiling and imaging in prognostication and surveillance.
• To address challenges in managing immunosuppressive therapies for CTD-ILD.

Main Methods:

• Review of existing literature on pulmonary manifestations in CTDs.
• Analysis of common pathologies including ILD, airway, pleural, and vascular involvement.
• Discussion of diagnostic and prognostic tools such as antibody profiling and imaging.
• Exploration of therapeutic strategies and their complications.

Main Results:

• Pulmonary involvement in CTDs is diverse, affecting airways, pleura, parenchyma, and vasculature.
• ILD is the predominant pulmonary finding, particularly in systemic sclerosis, rheumatoid arthritis, and inflammatory myopathies.
• Antibody profiling and imaging aid in prognostication.
• Distinguishing treatment failure from immunosuppression complications in CTD-ILD is challenging.

Conclusions:

• Pulmonary involvement, particularly ILD, is a significant complication of CTDs.
• Regular screening, prognostication using antibody profiles and imaging, and optimized surveillance are essential.
• Careful management of immunosuppressive therapies is critical to differentiate treatment effects from adverse events.